A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.

被引：5

作者：

Vaishampayan, Ulka N.

Narayan, Vivek

Wise, David

Lang, Joshua Michael

Lowentritt, Benjamin H.

Mellado, Begona

Carles, Joan

Saez, M. Isabel

Abida, Wassim

Taplin, Mary-Ellen

Azad, Arun

Wang, Karrie

Barbash, Olena

Ferron-Brady, Geraldine

Fecteau, Doug

Khaled, Ahmed Hussein

Dhar, Arindam

De Bono, Johann S.

机构：

[1] Karmanos Canc Ctr, Detroit, MI USA

[2] Penn Med Abramson Canc Ctr, Philadelphia, PA USA

[3] New York Univ Med Ctr, New York, NY USA

[4] Univ Wisconsin Carbone Canc Ctr, Madison, WI USA

[5] Chesapeake Urol Associates, Towson, MD USA

[6] Hosp Clin Barcelona, Barcelona, Spain

[7] Vall Hebron Univ Hosp Inst Oncol, Barcelona, Spain

[8] H Univ Virgen Victoria Reg Malaga, Inst Biomed Res Malaga CNIO IBIMA Genitourinary C, CRIS Canc Fdn Prostate Canc Res Grp, Malaga, Spain

[9] Mem Sloan Kettering Canc Ctr, New York, NY USA

[10] Dana Farber Canc Inst, Boston, MA USA

[11] Monash Univ, Clayton, Vic, Australia

[12] GlaxoSmithKline, Collegeville, PA USA

[13] Inst Canc Res & Royal Marsden Hosp, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期

关键词：

D O I：

10.1200/JCO.2018.36.6_suppl.TPS391

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS391

引用

页数：1

共 50 条

[31] An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate-resistant prostate cancer (CRPC)
MacVicar, G. R.
Greco, A.
Reeves, J.
Maleski, J.
Holmlund, J.
Leopold, L.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[32] Re: Activity and Safety of ODM-201 in Patients with Progressive Metastatic Castration-resistant Prostate Cancer (ARADES): An Open-label Phase 1 Dose-escalation and Randomised Phase 2 Dose Expansion Trial
Bjartell, Anders
EUROPEAN UROLOGY, 2015, 67 (02) : 348 - 349
[33] PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study
Petrylak, Daniel P.
Vogelzang, Nicholas J.
Chatta, Kamal
Fleming, Mark T.
Smith, David C.
Appleman, Leonard J.
Hussain, Arif
Modiano, Manuel
Singh, Parminder
Tagawa, Scott T.
Gore, Ira
McClay, Edward F.
Mega, Anthony E.
Sartor, A. Oliver
Somer, Bradley
Wadlow, Raymond
Shore, Neal D.
Olson, William C.
Stambler, Nancy
DiPippo, Vincent A.
Israel, Robert J.
PROSTATE, 2020, 80 (01): : 99 - 108
[34] Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study
McDermott, Raymond S.
Greene, John
McCaffrey, John
Parker, Imelda
Helanova, Sylva
Baird, Anne-Marie
Teiserskiene, Ausra
Lim, Marvin
Matthews, Helen
Deignan, Olwyn
Feeney, John
Thirion, Pierre G.
Finn, Stephen P.
Kelly, Paul J.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[35] A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer
Pook, David
Geynisman, Daniel M.
Carles, Joan
de Braud, Filippo
Joshua, Anthony M.
Perez-Gracia, Jose Luis
Perez, Casilda Llacer
Shin, Sang Joon
Fang, Bruno
Barve, Minal
Maruzzo, Marco
Bracarda, Sergio
Kim, Miso
Kerloeguen, Yannick
Gallo, Jorge Daniel
Maund, Sophia L.
Harris, Adam
Huang, Kuan-Chieh
Poon, Victor
Sutaria, Dhruvitkumar S.
Gurney, Howard
CLINICAL CANCER RESEARCH, 2023, 29 (17) : 3292 - 3300
[36] Phase 1/2a, open-label, dose-escalation and safety study of APC-100 in men with advanced prostate cancer.
Kyriakopoulos, Christos
Heath, Elisabeth I.
Eickhoff, Jens C.
Kolesar, Jill
Yayehyirad, Mulusew
Moll, Thomas
Liu, Glenn
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
[37] A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)
Sharp, Adam
Bernard-Tessier, Alice
Borchiellini, Delphine
de Bono, Johann
Fizazi, Karim
Gravis, Gwenaelle
Lorente, David
Mahammedi, Hakim
Mellado, Begona
Olmos, David
Pacey, Simon
Piulats, Jose
Ramirez, Sara P.
Gorbatchevsky, Igor
Heath, Elisabeth
CANCER RESEARCH, 2024, 84 (07)
[38] A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)
Heath, Elisabeth I.
Sharp, Adam
Borchiellini, Delphine
De Bono, Johann S.
Fizazi, Karim
Gravis, Gwenaelle
Lorente, David
Mahammedi, Hakim
Mellado-Gonzalez, Bego Na
Olmos, David
Pacey, Simon
Piulats, Josep M.
Ramirez, Sara Perez
Gorbatchevsky, Igor
Bernard-Tessier, Alice
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[39] A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Abida, Wassim
Bradley, Thomas Paul
Rezazadeh, Arash
Karsh, Lawrence Ivan
Ross, Ashley
Saltzstein, Daniel
Argon, Evren Kocabas
Hamlett, Anthony
Tang, Jeanie
Adib, Deyaa
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[40] A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA
Colomba, Emeline
Jonas, Sarah Flora
Eymard, Jean-Christophe
Delva, Remi
Brachet, Pierre Emmanuel
Neuzillet, Yann
Penel, Nicolas
Roubaud, Guilhem
Bompas, Emmanuelle
Mahammedi, Hakim
Longo, Raffaelle
Helissey, Carole
Barthelemy, Philippe
Borchiellini, Delphine
Hasbini, Ali
Priou, Franck
Saldana, Carolina
Voog, Eric
Narcisso, Berangere
Ladoire, Sylvain
Berdah, Jean-Francois
Aisenfarb, Jean-Baptiste
Foulon, Stephanie
Fizazi, Karim
EUROPEAN UROLOGY, 2024, 85 (03) : 274 - 282

← 1 2 3 4 5 →